• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.
【2h】

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

机译：使用新型多价黑素瘤疫苗进行主动特异性免疫治疗后，转移性黑素瘤的生存期延长。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A new polyvalent melanoma cell vaccine (MCV) was administered to 136 stage IIIA and IV (American Joint Committee on Cancer) melanoma patients. Induction of cell-mediated and humoral immune responses to common melanoma-associated antigens present on autologous melanoma cells was observed in patients receiving the new MCV. This was accompanied by increased activation of tumor-infiltrating lymphocytes. Survival correlated significantly with delayed cutaneous hypersensitivity (p = 0.0066) and antibody responses to MCV (p = 0.0117). Of 40 patients with evaluable disease, nine (23%) had regressions (three complete). From our historical database of 126 stage IIIA and 1275 stage IV melanoma patients, there were no significant changes in the natural history of metastatic melanoma during the past 20 years. Univariate and multivariate analyses demonstrated prognostic significance for site of metastases (p = 0.0001) and immunotherapy with the new MCV (p = 0.0001). Overall our new MCV increased the median and 5-year survival of stage IIIA melanoma patients with regional soft tissue metastases twofold (p = 0.00024), and stage IV patients threefold (p = 0.0001) compared with previous immunotherapy and other treatments.
机译：一种新的多价黑素瘤细胞疫苗（MCV）已用于136名IIIA和IV期（美国癌症联合委员会）黑素瘤患者。在接受新MCV的患者中，观察到对自体黑色素瘤细胞上存在的常见黑色素瘤相关抗原的细胞介导和体液免疫反应的诱导。这伴随着肿瘤浸润淋巴细胞的激活增加。存活率与延迟的皮肤超敏反应（p = 0.0066）和对MCV的抗体反应（p = 0.0117）显着相关。在40例可评估疾病患者中，有9例（23％）有消退（3例完成）。根据我们对126例IIIA期和1275期IV期黑素瘤患者的历史数据库，在过去20年中，转移性黑素瘤的自然史无明显变化。单因素和多因素分析显示了转移部位（p = 0.0001）和新MCV免疫治疗（p = 0.0001）的预后意义。总的来说，与先前的免疫治疗和其他治疗方法相比，我们新的MCV使具有局部软组织转移的IIIA期黑色素瘤患者的中位和5年生存率提高了两倍（p = 0.00024），而IV期患者的中位和5年生存率提高了三倍（p = 0.0001）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号